Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174401 · ClinicalTrials.gov registry record · Phase 4
Rocklatan Retinal Perfusion OCT Study
A Phase 4 study, sponsored by Oregon Health and Science University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07174401 is a Phase 4 study that has not yet begun recruiting, run by Oregon Health and Science University. The registered enrollment target is 30 participants.
The verdict
NCT07174401, a Phase 4 study, has not yet begun recruiting, sponsored by Oregon Health and Science University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.
Interventions
- DRUG Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months.
- DEVICE Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01 |
| Est. Completion | 2027-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07174401
The ClinicalTrials.gov registry entry for NCT07174401 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months. is the first listed.
NCT07174401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07174401 about?
NCT07174401 is a clinical study titled "Rocklatan Retinal Perfusion OCT Study". The main purpose of this study is to learn more about how Rocklatan eye drops affects blood flow in the eye. The secondary purpose is to see if our study devices can detect changes in blood flow before and after instillation of Rocklatan.
What is the current status of trial NCT07174401?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-01. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07174401?
The interventions under investigation include: Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months. (DRUG), Two optical coherence tomography (OCT) devices will be used to assess blood flow changes. (DEVICE).
Who is sponsoring clinical trial NCT07174401?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.